type here...

Health Care

Americans spend significantly more on health care than any other country. Why? Answers to this question range from hospital monopolies to perverse incentives to opaque pricing to medical licensing to pharmaceutical firms abusing IP practices to “creeping consolidation.” Why is the US health care system so broken? And what can antirust do about it? Catch-up on our coverage of antitrust and the US health care system.

Antitrust and Competition

Why the FTC Should Consider Size in Drug Mergers

Patricia M. Danzon
Large pharmaceutical firms retain their dominance through size-related advantages in three areas: contracting, marketing and selling, and financing. When reviewing pharmaceutical mergers, the Federal...
Antitrust and Competition

The Covid-19 Pandemic Should Not Delay Actions to Prevent Anticompetitive Consolidation in US Health Care Markets

Leemore Dafny
Harvard Business School professor Leemore Dafny lays out potential reforms to assist agencies in halting anticompetitive acquisitions and practices, and to preserve and promote...
Antitrust and Competition

Invigorating Competition in Health Care Markets: Is Rate Regulation Needed?

Tim Greaney
It now appears that market concentration may be the leading cause of America’s health care cost crisis. If the United States is going to...
Antitrust and Competition

Opening the Black Box: The Hidden Costs of Data-Driven Mergers in Health Care

Theodosia Stavroulaki
Vertical data-driven mergers between health insurers and drug suppliers may facilitate health insurers’ efforts to discriminate against vulnerable populations, leaving them without meaningful access...
Antitrust and Competition

How the FTC Protected the Market Power of Pharmacy Benefit Managers

Stacy Mitchell
Pharmacy Benefit Managers (PBMs) were established in the 1960s to control drug costs but have since morphed into one of the most highly concentrated...
Antitrust and Competition

What Is the Price of a Prescription Drug?

Robin Feldman
Due to lack of transparency and mystery rebates, which are considered trade secrets, figuring out the price of a prescription drug is devilishly difficult....
Covid-19

“The Way Insurance Companies Have Rigged Our Health Care System, They’re Probably Going to Emerge as Financial Winners from This”

Asher Schechter
Author and former health insurance executive Wendell Potter explains to ProMarket why the employer-based health care system in the US is “collapsing” and why health...
Antitrust and Competition

The Amazon of Health Care: How CVS Is Evolving From a Drug Store Chain into a Tech Platform

Matt Stoller
CVS is built on a dominant chain of drug stores, but it is now trying to turn itself into a "uniquely powerful platform" for...
Antitrust and Competition

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan
Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...
Antitrust and Competition

Hospital Mergers: The Forgotten Problem of American Health Care

Stefano Feltri
In the US, there are more than 100 hospital mergers every year. This increasing concentration does not lead to the promised savings, nor to...
123Page 2 of 3

Latest news

View All

The publication of the Stigler Center at The University of Chicago Booth School of Business

ProMarket is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not necessarily those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Policy.